GUIA DE SEGUIMIENTO FARMACOTERAPEUTICO SOBRE DIABETES PDF

que la mortalidad a largo plazo esté relacionada sobre todo con la recidiva de la enfermedad actuaciones en una guía de seguimiento del paciente trasplantado. . documento recoge recomendaciones farmacoterapéuticas, de autocuidado, de . de las guías. • Algunos pacientes pueden comenzar con una diabetes de. Efectividad del seguimiento farmacoterapéutico en diabéticos tipo 2 clínica, se obtuvo información sobre medicamentos antidiabéticos utilizados, dosis, .. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2. Objetivos: Realizar un seguimiento farmacoterapéutico y educar a pacientes conocimiento sobre la menopausia y la THR en pacientes menopaúsicas. Keywords: Hormone . ministerial que generará Guías Clínicas y tratará . stock de éste por el laboratorio que los produce. Diabetes. 38%. Depresión.

Author: Zubei Taum
Country: Sweden
Language: English (Spanish)
Genre: Education
Published (Last): 9 May 2006
Pages: 422
PDF File Size: 7.41 Mb
ePub File Size: 13.30 Mb
ISBN: 958-7-21335-768-9
Downloads: 38167
Price: Free* [*Free Regsitration Required]
Uploader: Arashibar

As with other studies, women were more willing to participate, which may be related to the greater prevalence of diabetes in this gender; with a mean age of 63 years sguimiento with overweight or obesity conditions 16 A guidance statement from the American College of Physicians. In Barranquilla, the prevalence of CKD is of approximately 46 persons perinhabitants 1.

Declaration of conflict of interest.

Universidad de Granada Grupo de Investigación en Atención Farmacéutica

Problemas de proceso y resultado relacionados con los medicamentos: Very frequently, the medical histories do not contain sufficient and necessary information for the case analysis in pharmacotherapeutical monitoring, given that many patients are seen by hired specialists, who generate reports different from those in the medical chart at the EPS, and access to this information is difficult in spite of multiple requests.

During the study, the patients were visited on at least three instances, establishing the NOMs in each visit. Each of the patients had a replacement selected randomly and with the same characteristics. Though patients were being treated with the medication for their basal disease, this was not yet controlled, and this triggered a higher likelihood of presenting other NOMs, and a higher risk to their health.

It was found that on the average, the patients were receiving 1. It is a useful tool for contributing to the adequate use of medications and guaranteeing their safe, effective, and economic use. Guide to drug dosage in renal failure.

Universidad de Granada Grupo de Investigación en Atención Farmacéutica [WorldCat Identities]

Mean age was Analysis per healthcare insurance carrier revealed that the difference in the mean ratio of the direct cost was in the range of 1. Parametric and non-parametric hypotheses tests were run for related samples, comparing the initial and final glycated hemoglobin within the same groups. After the intervention, the number of DRPs was reduced to 9 in 8 patients in total, which means that 22 patients did not present DRPs again, and Adis Internacional Limited, The design was Quasi-experimental, so that variables would not be intentionally modified, but interventions could be conducted that modified seguiimento final out-come of pharmacological treatment in patients.

  FILO PTERIDOPHYTA PDF

Problemas relacionados con los medicamentos como causa de consulta en el Servicio de Urgencias del Hospital Universitario Virgen de las Nieves de Granada. No important differences were found with the control group. Table 2 shows the NOM identified, with those relating to effectiveness being the most frequent It must be stated that the pharmacotherapeutic monitoring was carried out by the drug dispensing entity and not by the healthcare provider, for this reason the cost was not charged to the direct costs of patient healthcare.

We observed an average of 6. Through an interview and evaluation of medical records, we obtained information about antidiabetic medications used, doses, other medications, along with Hemoglobin A1c level, arterial pressure, serum low-density lipoprotein cholesterol level, nephropathy screening, retinal screening, farmacoterxpeutico exams in the last year and problems associated with medication use by means of the DADER method Negative Outcomes Associated with Medication NOM.

A total of 41 pharmaceutical interventions were conducted, 35 were accepted and 6 seguimienro not accepted.

Effectiveness the pharmaceutical care in diabetic patients* | Machado -Alba | Colombia Médica

The status of the condition was elaborated including diagnosis, each of the diabetees being taken, doses and dose intervals.

This was followed by Group A, Alimentary Tract, with prescriptions, and Group B, Blood and blood forming organs, with prescriptions; these two groups were the most widely used in all patients, due to their prophylactic nature. The likelihood of adverse effects was the main reason for NOM presentation. There no important variations or statistically significant differences in HbA1c values for patients in the intervention and control groups at the end of the study; although there was a reduction in values of glycated hemoglobin in the intervention group, making it convenient to suggest a similar study with a bigger population sample and a better control of losses.

To learn about the types of problems related to medications and negative outcomes associated with drugs that can be detected, prevented and solved in patients with chronic kidney disease, through pharmaceutical care practice. The selection and justification for seguijiento of medications was assessed; this way, Necessity NOMs were determined.

Diabetes mellitus DM is an increasingly occurring disease, which generates important complications that affect the quality of life of patients; hence, its care generates high costs, given that it is a disease of utmost interest for public health.

A quasi-experimental study was conducted, with a descriptive and retrospective design, in 47 hospitalized patients diagnosed with chronic kidney disease in a high-complexity clinic. The highest number of prescriptions presented in Group C, Cardiovascular System; and therefore, closer monitoring must be conducted for CKD. Diabetes in the Americas. All this based on good communication and cooperation between the patient and health personnel 9.

  FRANK MARGERIN LUCIEN PDF

Materials and method The design was Quasi-experimental, so that variables would not be intentionally modified, but interventions could be conducted that modified the final out-come of pharmacological treatment in patients. Diabetex these problems were detected and solved, pharmaceutical interventions were conducted verbally and in writing, with the aim of helping to improve the quality of life of patients, and therefore prevent their development.

Suggested interventions in pharmacotherapeutic monitoring, to correct this finding, may greatly benefit patients, possibly diminishing morbidity and mortality because of cardiocerebrovascular events associated to the use of said antiplatelet drug The situations that could be related to the loss of patients include: In terms of seguimienot, 13 patients were white, 5 patients were black, and 29 were of mixed race.

These findings suggest that the active involvement of Pharmacists in the treatment of renal anaemia for patients under hemodialysis had a great therapeutic impact.

The inability by patients to excrete drugs that are eliminated through the kidneys can lead to a build-up or metabolites, in case of repeated administration.

This finding warrants conducting a more profound study of the impact expected of pharmacotherapeutic monitoring on the cost of healthcare. Effectiveness NOMs were reviewed on the basis of the doses used and patient evolution, and Safety NOMs were detected through a comprehensive search in the Clinical Record about the slbre of any ADE Adverse Drug Event by analyzing the different treatments, identifying any potential drug interactions, a subsequent pharmaceutical interview, and the evolution of their health situation.

During each of the interviews of the patients in the intervention and control groups, we identified the NOM and the possible causes. Clinical pharmacy activities in chronic kidney disease and end-stage renal disease patients: There is also evidence in that the results of pharmaceutical care may lead to reduced utilization of healthcare services and to a lower number of medications aobre Safety was the NOM with the highest number of reports in terms of Non-Quantitative Insecurity, which means that in this case, dosing diabtes not a factor triggering this NOM.

Causes of NOM identified in the study patients can be seen in Table 3. Dose readjustments were conducted because treatments were not effective and safe, through pharmaceutical intervention.

After identifying NOM in each patient, the pharmacist suggested for the patients in the intervention group activities to solve the health problem associated to medication use, socializing said activities with the healthcare team through a written documment.